Equities

ReNeuron Group PLC

RENE:LSE

ReNeuron Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.38
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-53.45%
  • Beta1.1898
Data delayed at least 20 minutes.
More ▼

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Mar 31 2023202320222021
ASSETS
Cash And Short Term Investments7.151522
Total Receivables, Net1.411.562.05
Total Inventory------
Prepaid expenses0.270.370.23
Other current assets, total------
Total current assets8.841624
Property, plant & equipment, net0.620.660.69
Goodwill, net------
Intangibles, net0.190.190.19
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets9.651725
LIABILITIES
Accounts payable0.320.731.72
Accrued expenses3.856.144.01
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.150.150.16
Other current liabilities, total------
Total current liabilities4.327.025.88
Total long term debt0.270.420.56
Total debt0.420.560.72
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities4.597.446.45
SHAREHOLDERS EQUITY
Common stock0.570.570.57
Additional paid-in capital114114114
Retained earnings (accumulated deficit)(109)(105)(96)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity5.069.8919
Total liabilities & shareholders' equity9.651725
Total common shares outstanding575757
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.